Multiple myeloma
Conditions
Interventions
Teclistamab group:NA
Talquetamab group:NA
Sponsors
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. =18 years old when starting treatment. 2. RRMM disease. 3. Provide a signed informed consent form (ICF) . 4. Has received/will receive = 1 dose of Teclistamab/Talquetamab.
Exclusion criteria
Exclusion criteria: Is currently participating in an interventional clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR according to IMWG criteria; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient demographics, clinical characteristics and treatment history.;Treatment patterns, including prior regimen, combination, dosing and treatment line;CR or better rate;VGPR or better rate;Time to first response (TTR);Time to next treatment (TTNT);Duration of response (DOR);Progression-free survival (PFS);Overall survival (OS);Incidence, severity, concomitant treatment of prophylaxis and management of adverse events (AEs), including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, GPRC5D related AEs (skin-, nail-, and oral-related disorders), and other AEs, etc; | — |
Countries
China
Contacts
Public ContactLi Jian
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed